Are GlaxoSmithKline plc, SSE plc And Admiral Group plc The Best Income Stocks In The World?

Should you rush out to buy these 3 high-yielders? GlaxoSmithKline plc (LON: GSK), SSE PLC (LON: SSE) and Admiral Group plc (LON: ADM).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A year ago, it seemed likely that interest rates would have risen by at least 0.25% from their historic low. The UK economy was performing relatively well and while a General Election was on the horizon, it seemed as though ‘life support’ (i.e. a rock-bottom interest rate) was no longer necessary.

Today it looks like high-yielding stocks could remain in vogue for at least another year. Why?

The economy has performed relatively well in the last year but interest rates are no higher. Income-seeking investors continue to struggle since their cash balances are providing a relatively poor return. And while zero inflation means a real return on offer even from cash, a gross yield of around 2% is still very disappointing.

Looking ahead, interest rates could realistically remain at or near their lows over the next year simply because inflation is showing little sign of rising. 

Powerful pipeline

With a yield of 6%, GlaxoSmithKline (LSE: GSK) certainly has headline income appeal. It remains one of the highest yielding stocks in the FTSE 100 and although dividends per share are due to be frozen over the next couple of years, rapid dividend growth beyond that is very much on the horizon.

What’s behind that expected growth? GlaxoSmithKline’s drug pipeline is among the most diverse and appealing within the global pharmaceutical industry. It has multiple potential HIV treatments within its ViiV Healthcare division and with the company aiming to reduce costs by over £1bn in the coming years, it appears to have the right mix of sales growth potential as well as the scope to boost margins.

This is a key reason why GlaxoSmithKline is expected to increase its bottom line by 11% next year, which indicates that as well as being a strong income play, it also offers significant near-term growth potential.

Rising incomes

Similarly, SSE (LSE: SSE) also has a very desirable yield of 6.2% and unlike GlaxoSmithKline, its dividends are forecast to rise next year. The increase is expected to be just 1.6%, but that’s still ahead of inflation and so represents a real-term rise in shareholders’ incomes.

SSE also seems well-placed to at least match inflation when it comes to increases in shareholder payouts over the long term. Its dividends are currently covered 1.3 times by profit, which is relatively healthy. And its shares offer upside potential via a relatively appealing valuation. For example, SSE trades on a price to earnings (P/E) ratio of 12.7 indicating that it could deliver an excellent total return next year.

Steady as she goes

Meanwhile insurance business Admiral (LSE: ADM) currently yields 5.9% and while an increase to insurance premium tax has the potential to squeeze profitability within the car insurance sector, it appears to be well-positioned to overcome any such short term problems. The reason? The wide range of brands Admiral owns. They provide the company with a commanding position within the car insurance industry, allowing it to maintain relatively high levels of profitability.

As well as being a high-yielding stock, Admiral also offers a degree of consistency. For example, earnings increased in four of the last five years and with it having a beta of 0.86, it should offer a less volatile shareholder experience than many of its index peers in 2016.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Admiral Group, GlaxoSmithKline, and SSE. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying…

Read more »

Young black woman using a mobile phone in a transport facility
Market Movers

Meta stock slumps 13% after poor results. Here’s what I’ll do

Jon Smith flags up the reasons behind the fall in the Meta stock price overnight, along with his take on…

Read more »

Young Caucasian girl showing and pointing up with fingers number three against yellow background
Investing Articles

3 FTSE stocks I wouldn’t ‘Sell in May’

If the strategy had any merit in the past, I see no compelling evidence it's a smart idea today. Here…

Read more »